Skip to main content

Kline Kyle's Form 4/A amendment

Amended

Globus Medical Inc (GMED) · filed Jan 13, 2026

Accession no.
0001193125-26-011926
Filed
Jan 13, 2026
Trade date
Dec 1, 2025
Filing delay
43 days
Rule 10b5-1 plan
Not checked
Original filed
Dec 3, 2025

This filing lists 1 derivative transaction. It carries over 8 transactions from the original filing that it did not restate. Open-market sales total $1.67M. It was filed 43 days after the trade.

This amendment restates part of 0001193125-25-307215 (filed Dec 3, 2025). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kline KyleCIK 0002080625Officer (Senior Vice President, CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 1, 2025Class A Common StockMOption exerciseDisposed−4,896$0.00$0104Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001193125-25-307215 (filed Dec 3, 2025).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001193125-25-307215
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2025Class A Common StockMOption exerciseAcquired+3,646$53.14+$193,748.443,646Direct
Dec 1, 2025Class A Common StockMOption exerciseAcquired+5,000$56.43+$282,1508,646Direct
Dec 1, 2025Class A Common StockMOption exerciseAcquired+5,000$64.44+$322,20013,646Direct
Dec 1, 2025Class A Common StockMOption exerciseAcquired+4,896$63.68+$311,777.2818,542Direct
Dec 1, 2025Class A Common StockSSaleDisposed−18,542$90.00−$1,668,7800Direct

Derivative securities (Table II)

Derivative transactions carried over from 0001193125-25-307215
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 1, 2025Class A Common StockMOption exerciseDisposed−5,000$0.00$010,000Direct
Dec 1, 2025Class A Common StockMOption exerciseDisposed−5,000$0.00$00Direct
Dec 1, 2025Class A Common StockMOption exerciseDisposed−5,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On December 3, 2025, the reporting person filed a Form 4 which inadvertently reported in Table II that 5,000 options were exercised prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock that was reported in Table I. As correctly reported in this amendment, the reporting person exercised 4,896 options prior to the sale of the underlying 4,896 shares of the issuer's Class A Common Stock.

F2

These options were granted on January 27, 2022, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2023, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

Read the full filing on SEC EDGAR (opens in a new tab)